Hong Cen

ORCID: 0000-0003-2232-9213
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Acute Lymphoblastic Leukemia research
  • PI3K/AKT/mTOR signaling in cancer
  • Viral-associated cancers and disorders
  • CAR-T cell therapy research
  • T-cell and Retrovirus Studies
  • Immune Cell Function and Interaction
  • Liver Disease Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Drug-Induced Hepatotoxicity and Protection
  • Monoclonal and Polyclonal Antibodies Research
  • Hepatitis C virus research
  • Cutaneous lymphoproliferative disorders research
  • CNS Lymphoma Diagnosis and Treatment
  • MRI in cancer diagnosis
  • Advanced Neuroimaging Techniques and Applications
  • Cancer-related molecular mechanisms research
  • Virus-based gene therapy research
  • Hepatitis B Virus Studies
  • Peptidase Inhibition and Analysis
  • Advanced Breast Cancer Therapies
  • Liver Disease and Transplantation
  • Galectins and Cancer Biology

Guangxi Medical University
2009-2025

Tumor Hospital of Guangxi Medical University
2021-2025

Relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) is a rare and aggressive type of non-Hodgkin with limited treatment options. This phase II study evaluated the efficacy safety sugemalimab, an anti-PD-L1 monoclonal antibody, in R/R ENKTL.Eligible patients received sugemalimab 1,200 mg intravenously once every 3 weeks for up to 24 months until progression, death, withdrawal. The primary end point was objective response rate (ORR) assessed by independent radiologic...

10.1200/jco.22.02367 article EN cc-by-nc-nd Journal of Clinical Oncology 2023-03-30

Abstract Purpose: To investigate the efficacy and safety of novel orally active PI3Kδ inhibitor in relapsed and/or refractory patients with follicular lymphoma (FL) who had received at least two prior systemic treatments. Patients Methods: Histologically confirmed FL disease progression after receiving second-line or greater therapy were enrolled. Linperlisib was administered 80 mg every day, a 28-day cycle until intolerable toxicity occurred. The primary outcome for study objective response...

10.1158/1078-0432.ccr-22-2939 article EN cc-by-nc-nd Clinical Cancer Research 2023-02-03

Relapsed and/or refractory peripheral T-cell lymphoma (r/r PTCL) is an aggressive and heterogeneous hematologic malignancy with high unmet need. Previously, PI3K inhibitors were shown to be efficacious in B- lymphomas, but as a drug class, these agents have frequently been observed tolerability limitations. Next-generation that improve the while maintaining efficacy are desirable.

10.1158/1078-0432.ccr-24-1194 article EN Clinical Cancer Research 2024-09-19

7007 Background: Sintilimab monotherapy for cHL in third-line setting and beyond has been evaluated a single-arm, phase 2 study ORIENT-1. Here, we present results of the 3 ORIENT-21 evaluating sintilimab plus ICE versus placebo as second-line treatment cHL. Methods: This enrolled pts who have failed first-line standard chemotherapy. The safety run-in to enroll receiving ICE, followed by randomized which were assigned 1:1 ratio receive either (experimental arm) or (control 6 cycles. Patients...

10.1200/jco.2025.43.16_suppl.7007 article EN Journal of Clinical Oncology 2025-05-28

7013 Background: Patients (pts) with transplant-ineligible r/r DLBCL have an unmet need, objective response rate (ORR) of around 40%. CD79b, a key component the B-cell receptor and expressed in majority mature malignancies origin, is attractive therapeutic target for DLBCL. We initiated phase 1b/2 study to assess safety efficacy SHR-A1912, novel CD79b-targeted ADC, combination chemotherapy pts or treatment-naive Here, we report findings SHR-A1912 plus R-GemOx regimen cohort. Methods: The...

10.1200/jco.2025.43.16_suppl.7013 article EN Journal of Clinical Oncology 2025-05-28

This study compared the efficacy, safety and immunogenicity of ripertamab (SCT400) rituximab (Mabthera® ) combined with CHOP as first-line treatment for Chinese patients CD20-positive diffuse large B cell lymphoma (DLBCL). is a randomized, patient-blind, multicenter, active-control, non-inferiority parallel design. Patients were randomly (2:1) to receive (S-CHOP) or (R-CHOP) up 6 cycles. The primary endpoint was Independent Review Committee (IRC) assessed objective response rate (ORR) in...

10.1002/hon.3054 article EN Hematological Oncology 2022-07-20

7531 Background: PI3Kδ inhibitors have been shown to important roles in blocking mitogenic and survival signaling within the tumor cell microenvironment activate antilymphoma immune responses. Linperlisib is an oral highly selective small molecule inhibitor of has demonstrated be well-tolerated with a favorable PK profile patients lymphomas at RP2D. This phase Ib study evaluating efficacy safety relapsed or refractory peripheral T-cell lymphoma (PTCL), aggressive malignancy few treatment...

10.1200/jco.2021.39.15_suppl.7531 article EN Journal of Clinical Oncology 2021-05-20

Abstract The diagnostic efficiency of diffusion-weighted magnetic resonance imaging with different b -values and application an intravoxel incoherent motion (IVIM) model for differentiating disease states lymphoma was investigated. Thirty-six patients at initial diagnosis 69 after chemotherapy underwent (DW-MRI) multiple -values. Analysis parameters included the apparent diffusion coefficient (ADC) each -value. Standard ADC, D , ∗, f were calculated using IVIM model. For diagnosis, compared...

10.1097/md.0000000000014459 article EN cc-by-nc Medicine 2019-02-01

<div>AbstractPurpose:<p>Relapsed and/or refractory peripheral T-cell lymphoma (r/r PTCL) is an aggressive and heterogeneous hematologic malignancy with high unmet need. Previously, PI3K inhibitors were shown to be efficacious in B- lymphomas, but as a drug class, these agents have frequently been observed tolerability limitations. Next-generation that improve the while maintaining efficacy are desirable.</p>Patients Methods:<p>A phase Ib clinical study was conducted...

10.1158/1078-0432.c.7494019 preprint EN 2024-10-15

Background: specialized studies on hepatitis B virus (HBV) infection and B-NHL (B-cell Non-Hodgkin’s Lymphoma) are limited, as well prophylactic antiviral therapy for patients with HBV who receiving anticancer chemotherapy. This study aims to investigate the association between B-NHL, evaluate effect of HBV-infected patients. Study design: A retrospective, case-control was performed. The group included 420 were consecutively diagnosed from May 2003 October 2013 (age range, 14 - 71 years),...

10.4236/health.2016.85053 article EN Health 2016-01-01

<div>AbstractPurpose:<p>To investigate the efficacy and safety of novel orally active PI3Kδ inhibitor in relapsed and/or refractory patients with follicular lymphoma (FL) who had received at least two prior systemic treatments.</p>Patients Methods:<p>Histologically confirmed FL disease progression after receiving second-line or greater therapy were enrolled. Linperlisib was administered 80 mg every day, a 28-day cycle until intolerable toxicity occurred. The primary...

10.1158/1078-0432.c.6533216.v1 preprint EN 2023-04-01
Coming Soon ...